SandboxAB: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 41: | Line 41: | ||
|} | |} | ||
<BR> | <BR> | ||
*Being the most common cause of cystitis(75-90%), E.Coli susceptibility test should be considered to choose the appropriate empirical antimicrobial. | |||
*Being the most common cause of cystitis(75-90%), E.Coli susceptibility test should be considered to choose the appropriate empirical antimicrobial.Other organisms like Proteus mirabilis, Klebsiella pneumoniae and Staphylococcus saprophyticus are far less common. | |||
*[[Nitrofurantoin]], [[fosfomycin]] and mecillinam are prefered as first line treatment because have less resistance among other antibacterials. | *[[Nitrofurantoin]], [[fosfomycin]] and mecillinam are prefered as first line treatment because have less resistance among other antibacterials. | ||
Line 51: | Line 51: | ||
*[[Nitrofurantoin]], [[fosfomycin]] and mecillinam shouldn't be used when pyelonephritis is suspected, because they have weak penetration to the renal tissue. | *[[Nitrofurantoin]], [[fosfomycin]] and mecillinam shouldn't be used when pyelonephritis is suspected, because they have weak penetration to the renal tissue. | ||
*Use of broad-spectrum antimicrobials resulted multi-drug resistant organisms, so they are used as alternative to the first line drugs in case of allergy, availability, or tolerance. | *Use of broad-spectrum antimicrobials resulted multi-drug resistant organisms, so they are used as alternative to the first line drugs in case of allergy, availability, or tolerance. | ||
<br> | |||
{| | |||
|- | |||
| valign=top | | |||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:25em" cellpadding="0" cellspacing="0"; | |||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B| Acute Bacterial Uncomplicated Pyelonephritis}}'' | |||
|- | |||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluoroquinolones]]'''''<br>'''''[[Ciprofloxacin]] 500 mg PO bid ×7 days'''''<br>'''''[[Levofloxacin]] 750 mg PO q24 × 5 days '''''<br> | |||
|- | |||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen(14 day regimen)'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[TMP-SMX]] 160/800 mg PO bid'''''<br>OR<br>'''''▸ Oral[[β-lactam]]<br>[[Amoxicillin-clavulanate]] 875/125 mg po q12h or 500/125 mg po tid or 1000 /125 mg po bid <br>[[Cefdinir]] 300 mg po q12h or 600 mg po q24 <br>[[Cefaclor]] 250-500 mg po q8h<br>[[Cefpodoxime-proxetil]] 100-200 mg po q12h<br>[[Cephalexin]]250-500 mg po q6h not studied well but effective.''''' | |||
|- | |||
|} |
Revision as of 09:13, 17 January 2014
‡Avoid if resistance prevalence is known to exceed 20% or if used for UTI in previous 3 months. ♦Pivmecillinam is available in some European countries, not licensed in US.
|